BIOL - Biolase Inc Stock Price, Fair Value and News

0.16USD0.00 (0.00%)Delayed

Market Summary

USD0.160.00

Delayed

0.00%

BIOL Stock Price

View Fullscreen

BIOL RSI Chart

BIOL Valuation

Market Cap

5.3M

Price/Earnings (Trailing)

-0.25

Price/Sales (Trailing)

0.11

EV/EBITDA

-0.64

Price/Free Cashflow

-0.35

BIOL Price/Sales (Trailing)

BIOL Profitability

Operating Margin

34.25%

EBT Margin

-43.46%

Return on Equity

1.1K%

Return on Assets

-61.91%

Free Cashflow Yield

-282.51%

BIOL Fundamentals

BIOL Revenue

Revenue (TTM)

48.8M

Rev. Growth (Yr)

-3.21%

Rev. Growth (Qtr)

-24.9%

BIOL Earnings

Earnings (TTM)

-21.3M

Earnings Growth (Yr)

-10.87%

Earnings Growth (Qtr)

-21.76%

Breaking Down BIOL Revenue

Last 7 days

-5.9%

Last 30 days

6.7%

Last 90 days

6.7%

Trailing 12 Months

-99%

How does BIOL drawdown profile look like?

BIOL Financial Health

Current Ratio

1.17

Debt/Equity

-5.79

Debt/Cashflow

-1.28

BIOL Investor Care

Shares Dilution (1Y)

3114.29%

Diluted EPS (TTM)

-16.07

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	48.8M	0	0	0
2023	48.8M	50.8M	49.7M	49.2M
2022	41.2M	44.3M	46.8M	48.5M
2021	26.1M	32.3M	35.3M	39.2M
2020	32.3M	26.5M	24.4M	22.8M
2019	46.5M	43.0M	40.7M	37.8M
2018	46.1M	45.6M	45.7M	46.2M
2017	51.7M	50.5M	48.1M	46.9M
2016	48.6M	50.6M	52.6M	51.8M
2015	47.0M	48.7M	47.2M	48.5M
2014	53.4M	49.3M	49.7M	47.7M
2013	59.6M	61.7M	60.3M	56.4M
2012	50.6M	51.1M	51.8M	57.4M
2011	30.7M	36.5M	43.4M	48.9M
2010	0	37.1M	30.8M	24.6M
2009	0	0	0	43.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biolase Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 07, 2022	lord jonathan t md	sold	-2,652	0.75	-3,537	-
Apr 28, 2022	roper jess	back to issuer	-	-	-345	-
Apr 28, 2022	beaver john r	back to issuer	-	-	-554	president & ceo
Apr 28, 2022	lord jonathan t md	back to issuer	-	-	-1,395	-
Dec 15, 2021	lord jonathan t md	sold	-4,194	0.38	-11,038	-
Nov 30, 2021	beaver john r	bought	31,500	0.45	70,000	president & ceo
Aug 20, 2021	beaver john r	bought	21,350	0.61	35,000	president & ceo
May 19, 2021	beaver john r	bought	30,000	0.75	40,000	president & ceo
Dec 18, 2020	schuler education foundation	sold	-52,576	0.28	-187,774	-
Dec 17, 2020	schuler education foundation	sold	-160,348	0.28	-572,671	-

Which funds bought or sold BIOL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	new	-	1,919	1,919	-%
May 15, 2024	MORGAN STANLEY	sold off	-100	-16.00	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-26.00	-	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	14.00	14.00	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-91.83	-2,707	38.00	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	22,143	22,143	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-12,035	-	-%
May 15, 2024	Royal Bank of Canada	new	-	9,000	9,000	-%
May 15, 2024	CITADEL ADVISORS LLC	added	188	-7,916	7,560	-%
May 14, 2024	Qube Research & Technologies Ltd	new	-	759	759	-%

Are Funds Buying or Selling BIOL?

Are funds buying BIOL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BIOL

No. of Funds

Unveiling Biolase Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 23, 2024	s.h.n. financial investments ltd.	9.9%	1,190,000	SC 13G
Feb 21, 2024	lind global fund ii lp	9.9%	1,190,000	SC 13G
Feb 14, 2024	anson funds management lp	8.1%	185,127	SC 13G
Feb 14, 2024	lytton laurence w	0.6%	26,824	SC 13G/A
Feb 13, 2024	lind global fund ii lp	0.4%	9,210	SC 13G/A
Oct 10, 2023	krefta edson roberto	10%	107,225	SC 13G/A
Sep 12, 2023	krefta edson roberto	6.8%	71,000	SC 13G
May 15, 2023	perkins capital management inc	2.1%	689,196	SC 13G/A
Feb 09, 2023	perkins capital management inc	11.9%	3,288,581	SC 13G
Jan 20, 2023	lytton laurence w	9.99%	2,461,094	SC 13G

Recent SEC filings of Biolase Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 06, 2024	8-K	Current Report
Apr 23, 2024	424B4	Prospectus Filed
Apr 22, 2024	EFFECT	EFFECT
Apr 19, 2024	8-K	Current Report
Apr 19, 2024	POS AM	POS AM
Apr 11, 2024	POS AM	POS AM
Apr 04, 2024	424B3	Prospectus Filed

Peers (Alternatives to Biolase Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Biolase Inc News

Latest updates

Biolase Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-24.9%	10,131,000	13,490,000	10,921,000	14,286,000	10,467,000	14,051,000	12,010,000	12,235,000	10,166,000	12,407,500	9,531,000	9,134,000	8,116,000	8,520,000	6,539,000	2,938,000	4,783,000	10,182,000	8,646,000	8,645,000	10,326,000
Cost Of Revenue	-31.8%	6,795,000	9,966,500	7,175,000	8,168,000	7,130,000	10,455,000	9,565,000	7,094,000	5,437,000	7,502,000	4,689,000	5,093,000	5,375,000	6,915,000	4,265,000	1,997,000	3,430,000	5,765,000	5,677,000	5,265,000	6,804,000
Gross Profit	-5.3%	3,336,000	3,523,500	3,746,000	6,118,000	3,337,000	3,596,000	2,445,000	5,141,000	4,729,000	4,905,500	4,842,000	4,041,000	2,741,000	1,605,000	2,274,000	941,000	1,353,000	4,417,000	2,969,000	3,380,000	3,522,000
Operating Expenses	-8.6%	7,862,000	8,600,000	7,443,000	9,990,000	8,628,000	12,022,500	10,096,000	10,196,000	8,935,000	9,335,000	7,499,000	7,324,000	8,803,000	7,143,500	5,941,000	4,920,000	6,705,000	7,460,000	7,851,000	6,717,000	7,886,000
S&GA Expenses	-20.0%	3,383,000	4,227,500	3,402,000	6,189,000	4,622,000	6,451,000	5,008,000	5,402,000	4,814,000	5,024,000	3,451,000	3,311,000	3,553,000	3,767,000	2,678,000	2,093,000	2,704,000	3,730,500	3,515,000	3,272,000	3,879,000
R&D Expenses	-22.3%	1,283,000	1,651,500	1,362,000	1,444,000	1,547,000	2,088,500	1,979,000	1,653,000	1,544,000	1,542,500	1,540,000	1,162,000	1,803,000	1,051,000	963,000	690,000	991,000	1,095,500	1,126,000	1,124,000	1,424,000
EBITDA Margin	-1.2%	-0.33	-0.32	-0.42	-0.50	-0.56	-0.55	-0.47	-0.38	-0.29	-0.36	-0.42	-0.35	-0.58	-	-	-	-	-	-	-	-
Interest Expenses	-1.0%	494,000	499,000	489,000	460,000	470,000	409,000	367,000	366,000	377,000	443,000	442,000	438,000	448,000	443,000	972,000	-19,000	485,000	469,000	484,000	401,000	430,000
Income Taxes	222.6%	19,000	-15,500	15,000	31,000	1,000	86,000	-17,000	23,000	17,000	71,500	14,000	-80,000	60,000	143,000	-15,000	53,000	-19,000	-112,500	26,000	28,000	15,000
Earnings Before Taxes	-21.1%	-6,466,000	-5,341,500	-4,574,000	-4,837,000	-5,848,000	-9,774,500	-8,404,000	-5,588,000	-4,759,000	-5,207,500	-3,262,000	-782,000	-6,841,000	-6,061,000	27,000	-4,644,000	-6,025,000	-3,695,000	-5,452,000	-3,871,000	-4,885,000
EBT Margin	-3.7%	-0.43	-0.42	-0.50	-0.57	-0.61	-0.59	-0.51	-0.42	-0.34	-0.41	-0.48	-0.42	-0.67	-	-	-	-	-	-	-	-
Net Income	-21.8%	-6,485,000	-5,326,000	-4,589,000	-4,868,000	-5,849,000	-9,860,500	-8,387,000	-5,611,000	-4,776,000	-5,279,000	-3,276,000	-702,000	-6,901,000	-6,140,000	12,000	-4,697,000	-6,006,000	-3,582,500	-5,478,000	-3,899,000	-4,900,000
Net Income Margin	-3.8%	-0.44	-0.42	-0.51	-0.57	-0.61	-0.59	-0.51	-0.43	-0.34	-0.41	-0.48	-0.42	-0.68	-	-	-	-	-	-	-	-
Free Cashflow	-140.6%	-5,938,000	-2,468,000	-2,770,000	-3,919,000	-6,245,000	-6,053,000	-9,224,000	-6,886,000	-8,325,000	-3,415,000	-3,683,000	-3,812,000	-6,507,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.1%	34.00	35.00	39.00	40.00	42.00	38.00	43.00	51.00	50.00	55.00	59.00	61.00	63.00	41.00	42.00	28.00	25.00	32.00	28.00	32.00	34.00
Current Assets	0.6%	25.00	25.00	28.00	28.00	32.00	29.00	34.00	44.00	44.00	49.00	53.00	55.00	58.00	35.00	36.00	23.00	20.00	27.00	23.00	27.00	29.00
Cash Equivalents	-3.1%	6.00	7.00	8.00	7.00	7.00	4.00	10.00	20.00	22.00	30.00	34.00	37.00	41.00	18.00	19.00	6.00	2.00	6.00	2.00	4.00	3.00
Inventory	-1.4%	11.00	11.00	14.00	13.00	18.00	16.00	16.00	17.00	15.00	13.00	14.00	13.00	12.00	11.00	13.00	12.00	12.00	11.00	12.00	12.00	12.00
Net PPE	-12.3%	5.00	6.00	6.00	6.00	5.00	4.00	4.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00
Goodwill	0%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	2.8%	34.00	33.00	33.00	32.00	34.00	33.00	29.00	29.00	30.00	30.00	28.00	28.00	30.00	31.00	28.00	26.00	25.00	28.00	29.00	29.00	27.00
Current Liabilities	9.0%	21.00	20.00	20.00	18.00	19.00	18.00	14.00	14.00	13.00	14.00	13.00	13.00	11.00	11.00	21.00	21.00	24.00	26.00	14.00	13.00	15.00
Long Term Debt	-4.9%	11.00	12.00	-	-	-	13.00	-	-	-	-	-	-	-	16.00	-	-	-	-	13.00	13.00	11.00
LT Debt, Current	23.6%	3.00	2.00	-	-	-	1.00	-	-	-	-	-	-	-	-	13.00	14.00	14.00	13.00	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.00	-	-	-	-	13.00	13.00	11.00
Shareholder's Equity	-683.0%	-1.93	-0.25	0.00	7.00	8.00	5.00	14.00	22.00	21.00	25.00	30.00	33.00	34.00	10.00	14.00	1.00	0.00	0.00	-	4.00	7.00
Retained Earnings	-2.0%	-323	-316	-311	-306	-302	-296	-286	-277	-272	-267	-262	-258	-258	-251	-245	-245	-240	-234	-230	-225	-221
Additional Paid-In Capital	1.5%	322	317	313	314	311	302	0.00	0.00	0.00	293	293	293	292	262	259	247	236	236	231	230	229
Shares Outstanding	873.6%	33.00	3.00	2.00	1.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-
Float	-	-	-	-	7.00	-	-	-	-	-	-	-	104	-	-	-	104	-	-	-	12.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-160.1%	-5,938	-2,283	-2,588	-3,562	-5,658	-5,582	-6,546	-6,612	-8,021	-3,104	-3,598	-3,509	-6,499	-1,348	-2,108	-5,205	-4,134	-4,672	-1,447	-1,593	-5,034
Share Based Compensation	-37.9%	113	182	275	84.00	691	612	591	891	209	174	191	369	928	1,003	848	800	719	768	770	447	757
Cashflow From Investing	6666.7%	197	-3.00	-182	-357	-587	-471	-2,678	-274	-304	-311	-85.00	-303	-8.00	-18.00	3.00	-72.00	-9.00	-69.00	-13.00	-117	-8.00
Cashflow From Financing	538.1%	5,647	885	3,756	4,276	8,517	-32.00	-214	4,849	-	68.00	75.00	-14.00	29,825	-53.00	15,391	9,128	-117	8,305	-50.00	2,463	3.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BIOL Income Statement

2024-03-31

Condensed Consolidated Statements Of Operations And Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenue	$ 10,131	$ 10,467
Cost of revenue	6,795	7,130
Gross profit	3,336	3,337
Operating expenses:
Sales and marketing	3,383	4,622
General and administrative	3,196	2,459
Engineering and development	1,283	1,547
Total operating expenses	7,862	8,628
Loss from operations	(4,526)	(5,291)
Gain (loss) on foreign currency transactions	(96)	20
Interest expense, net	(622)	(577)
Other income (loss), net	(1,222)	0
Non-operating loss, net	(1,940)	(557)
Loss before income tax provision	(6,466)	(5,848)
Income tax provision	(19)	(1)
Net loss	(6,485)	(5,849)
Other comprehensive loss items:
Foreign currency translation adjustments	(86)	80
Comprehensive loss	(6,571)	(5,769)
Net loss	(6,485)	(5,849)
Deemed dividend on convertible preferred stock	0	0
Net loss attributable to common stockholders	$ (6,485)	$ (5,849)
Net loss per share attributable to common stockholders:
Earnings Per Share, Basic	$ (0.36)	$ (17.83)
Earnings Per Share, Diluted	$ (0.36)	$ (17.83)
Shares used in the calculation of net loss per share:
Weighted Average Number of Shares Outstanding, Basic	17,842	328
Weighted Average Number of Shares Outstanding, Diluted	17,842	328

BIOL Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,393	$ 6,566
Accounts receivable, less allowance of $216 and $244 as of March 31, 2024 and December 31, 2023, respectively	5,687	5,483
Inventory	11,273	11,433
Prepaid expenses and other current assets	1,652	1,381
Total current assets	25,005	24,863
Property, plant, and equipment, net	4,846	5,525
Goodwill	2,926	2,926
Right-of-use assets, leases	1,313	1,519
Other assets	263	268
Total assets	34,353	35,101
Current liabilities:
Accounts payable	4,915	6,065
Accrued liabilities	7,589	7,518
Stock warrant liability	3,780	1,363
Deferred revenue, current portion	2,343	2,452
Current portion of term loans	2,800	2,265
Total current liabilities	21,427	19,663
Deferred revenue	223	256
Warranty accrual	598	593
Non current term loans, net of discount	11,207	11,782
Non current operating lease liability	542	772
Other liabilities	87	79
Total liabilities	34,084	33,145
Mezzanine Equity:
Total mezzanine equity	2,203	2,203
Stockholders' equity:
Common stock, par value $0.001 per share; 180,000 shares authorized, 33,257 and 3,416 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	33	3
Additional paid-in-capital	321,957	317,103
Accumulated other comprehensive loss	(639)	(553)
Accumulated deficit	(323,285)	(316,800)
Total stockholders' equity (deficit)	(1,934)	(247)
Total liabilities, convertible redeemable preferred stock and stockholders' equity (deficit)	34,353	35,101
Series H Preferred Stock [Member]
Mezzanine Equity:
Preferred stock Value	346	346
Series J Convertible Preferred Stock [Member]
Mezzanine Equity:
Preferred stock Value	$ 1,857	$ 1,857

About Biolase Inc

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, therapy pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

CEO	Mr. John R. Beaver
WEBSITE	biolase.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	188

Biolase Inc Frequently Asked Questions

What is the ticker symbol for Biolase Inc? What does BIOL stand for in stocks?

BIOL is the stock ticker symbol of Biolase Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biolase Inc (BIOL)?

As of Fri May 17 2024, market cap of Biolase Inc is 5.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIOL stock?

You can check BIOL's fair value in chart for subscribers.

What is the fair value of BIOL stock?

You can check BIOL's fair value in chart for subscribers. The fair value of Biolase Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biolase Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIOL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biolase Inc a good stock to buy?

The fair value guage provides a quick view whether BIOL is over valued or under valued. Whether Biolase Inc is cheap or expensive depends on the assumptions which impact Biolase Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIOL.

What is Biolase Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BIOL's PE ratio (Price to Earnings) is -0.25 and Price to Sales (PS) ratio is 0.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIOL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Biolase Inc's stock?

In the past 10 years, Biolase Inc has provided -0.694 (multiply by 100 for percentage) rate of return.